Matinas BioPharma Holdings (MTNB) Amortization of Deferred Charges (2020 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Amortization of Deferred Charges of $74000.0 for Q1 2026, down 32.11% year-over-year from $109000.0 in Q1 2025, and down 18.68% quarter-over-quarter from $91000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Amortization of Deferred Charges for 7 consecutive years, with $74000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 32.11% year-over-year to $74000.0; the TTM figure through Mar 2026 stood at $387000.0 (down 31.63% YoY), while the FY2025 annual figure was $420000.0, down 30.23% from the prior year.
- Amortization of Deferred Charges slipped to $74000.0 in Q1 2026 per MTNB's latest filing, from $91000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $156000.0 in Q4 2024 and bottomed at $74000.0 in Q1 2026.
- Historically, Amortization of Deferred Charges has averaged $128705.9 across 5 years, with a median of $136000.0 in 2022.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges advanced 19.83% — and 2025, when it sank 41.67%.
- Matinas BioPharma Holdings' Amortization of Deferred Charges stood at $129000.0 in 2022, then climbed by 10.08% to $142000.0 in 2023, then grew by 9.86% to $156000.0 in 2024, then sank by 41.67% to $91000.0 in 2025, then declined by 18.68% to $74000.0 in 2026.
- Business Quant data shows MTNB's Amortization of Deferred Charges at $74000.0 in Q1 2026, $91000.0 in Q4 2025, and $111000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,000.00 |
| Jun 30, 2026 | 3,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | 91,000.00 |
| Dec 31, 2025 | 91,000.00 |
| Sep 30, 2025 | 111,000.00 |
| Sep 30, 2025 | 111,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Mar 31, 2024 | 145,000.00 |
| Mar 31, 2024 | 145,000.00 |